American pharma major Eli Lilly sees India as its launchpad for a new growth trajectory, using its new drugs for diabetes and obesity as the fuel. Will this strategic pivot work? - Issue Date: Mar 31, 2024
IvyCap Ventures sells stake in Pharmarack at 104 pc IRR
Homegrown VC fund IvyCap had invested Rs 21 crore in B2B healthcare platform Pharmarack in 2019.
0 claps
Homegrown venture capital (VC) fund
IvyCap Ventures on Monday announced the sale of its stake in business-to-business (B2B) healthcare platform Pharmarack at an annual internal rate of return (IRR) of 104 percent.
IvyCap had invested Rs 21 crore in Pharmarack in 2019.
Pharmarack combines technology, analytics, logistics, supply chain, and financing and is an ecosystem partner for pharmaceutical and consumer health companies, distributors, retailers, hospitals, and public health enterprises.
A statement released by IvyCap said Pharmarack counts several top 20 pharma companies as clients and its extensive value chain covers 200,000 pharmacies, more than 5,000 pharma distributors, and 200 hospitals. The platform claims to cover around 1,000 pin codes in the country. Its neutral network, flexible integration, and digi